The FDA application for approval of zanidatamab is based on encouraging data from the Phase IIb HERIZON-BTC-01 clinical trial in patients with previously treated unresectable locally advanced or metastatic HER2-positive biliary tract cancer.
FDA Grants Priority Review to Jazz Pharmaceuticals’ Zanidatamab for the Treatment of Multiple Forms of HER-2-Positive Biliary Tract Cancer
Leave a comment
